Cybin is trading 12.4% up at $7.32 in pre-market following bullish analyst coverage and commentary regarding its strengthened cash position.
- Analysts cited ongoing clinical progress in the company’s psychedelic programs as a primary driver for the positive sentiment.
- The upward move is further supported by balance sheet reinforcement, providing the company with a more stable financial outlook for its development pipeline.